(Q81460442)
Statements
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors (English)
Scot Ebbinghaus
Eric Rubin
Evan Hersh
Lee D Cranmer
Peter L Bonate
Robert J Fram
Antti Jekunen
Steve Weitman